tirzepatide soln auto-injector Lilly's Mounjaro receives FDA approval for type 2 diabetes treatment reducing glucagon (a hormone that raises blood sugar) Mounjaro (Tirzepatide) Injection 12.5 mg/0.5
Description
EB has received research support and speaker honoraria, and has served on an advisory board for Novo Nordisk
The side effect profile is similar in type, with nausea, constipation, and diarrhea being most common, but the severity and tolerability may differ due to the different receptor activation pattern
But the landscape shifted dramatically in early 2025, and understanding the current regulatory environment is critical before exploring this option
Those who experienced nausea at the initial dose may see a brief return of symptoms when stepping up, typically lasting two to three days
Like many people, I have struggled with my weight for most of my adult life
Follow manufacturer instructions to unlock and prime the pen if required (most tirzepatide pens are pre-set and do not require priming)
